Search results for " Combination"

showing 10 items of 923 documents

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C …

2008

Background and aim We assessed whether the two regimens of pegylated alpha-interferon-2b (PEG-IFN-alpha2b) plus ribavirin and pegylated alpha-interferon-2a (PEG-IFN-alpha2a) plus ribavirin showed differences in terms of sustained virological response, withdrawal due to side-effects and dose adjustment requirements in the treatment of naive chronic hepatitis C virus (HCV) patients. Methods A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha2a/ribavirin, n = 91; PEG-IFN-alpha2b/ribavirin, n = 92). Results Sustained virologi…

AdultMalemedicine.medical_specialtyHepacivirusHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundInterferonInternal medicineRibavirinmedicineHumansProspective StudiesProspective cohort studyHepatologymedicine.diagnostic_testbiologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseRecombinant ProteinsTreatment OutcomechemistryLiver biopsyImmunologyDrug Therapy CombinationFemalebusinessViral loadmedicine.drugJournal of gastroenterology and hepatology
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Effect of dual blockade of renin–angiotensin system on TGFβ1 and left ventricular structure and function in hypertensive patients

2007

The effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor beta1 (TGFbeta1), procollagen type I (PIP) and III (PIIIP), have been evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/ daily) and combined (losartan 50 mg/daily + ramipril 5 mg/daily) for 24 weeks. TGFbeta1, PIP and PIIIP, LVM, LVM/h(2.7) and other echo…

AdultMalemedicine.medical_specialtyLeft ventricular structureHeart VentriclesBlood PressureEnzyme-Linked Immunosorbent AssayAngiotensin II Receptor BlockersPeptide hormoneSeverity of Illness IndexDual blockadeCollagen Type ILosartanVentricular Function LeftRenin-Angiotensin SystemTransforming Growth Factor beta1Double-Blind MethodRamiprilInternal medicineRenin–angiotensin systemPrevalenceInternal MedicineHumansMedicineAntihypertensive AgentsUltrasonographyAnalysis of Variancebusiness.industryMiddle AgedAngiotensin IICollagen Type IIITreatment OutcomeEndocrinologyItalyHypertensionACE inhibitorDrug Therapy CombinationFemaleHypertrophy Left VentricularbusinessBiomarkersmedicine.drugJournal of Human Hypertension
researchProduct

Arterial Destiffening in Previously Untreated Mild Hypertensives After 1 Year of Routine Clinical Management

2016

BACKGROUND Arterial stiffness, measured with pulse wave velocity (PWV), is now classified as a marker of target organ damage (TOD) alongside left ventricular hypertrophy and moderately increased albuminuria. Interventional studies on treated hypertensive patients have shown that PWV could be improved. Our aim was to assess changes in arterial stiffness after 1 year of routine clinical practice in never-treated hypertensive patients. PATIENTS AND METHODS We studied 356 never-treated patients with suspected hypertension. After standard clinical assessment during which presence of TOD was evaluated, hypertension diagnosis was confirmed in 231 subjects who subsequently received standard routine…

AdultMalemedicine.medical_specialtyMean arterial pressureTime FactorsVasodilationPulse Wave Analysis030204 cardiovascular system & hematologyLeft ventricular hypertrophy03 medical and health sciencesVascular Stiffness0302 clinical medicineInternal medicineHeart ratePrevalenceInternal MedicineHumansMedicineArterial Pressure030212 general & internal medicinePulse wave velocityAntihypertensive Agentsbusiness.industryMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeBlood pressureSpainCase-Control StudiesHypertensionAlbuminuriaArterial stiffnessCardiologyDrug Therapy CombinationFemalemedicine.symptombusinessAmerican Journal of Hypertension
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct

Aggressive Pharmacological Treatment for Reversing Malignant Bowel Obstruction

2004

Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also reverse malignant bowel obstruction. Fifteen consecutive advanced cancer patients with inoperable bowel obstruction received a combination of drugs including metoclopramide, octreotide, dexamethasone and an initial bolus of amidotrizoato. Recovery of intestinal transit was reported within 1-5 days in fourteen patients, who continued this treatment without presenting symptoms of bowel obstruction until death. This case series establishes that the combination of propulsive and antisecretive agents can act synergistically to allow a fast recovery of bowel transit without inducing unpleasant col…

AdultMalemedicine.medical_specialtyMetoclopramidemedicine.drug_classOctreotideGastroenterologyBolus (medicine)Gastrointestinal AgentsInternal medicineEdemamedicineHumansGeneral NursingDexamethasoneAgedPelvic NeoplasmsTerminal Carebusiness.industrydigestive oral and skin physiologyPalliative CareFecal impactionDrug SynergismRecovery of FunctionMiddle Agedmedicine.diseasedigestive system diseasesBowel obstructionDrug CombinationsAnesthesiology and Pain MedicineTreatment OutcomeAnesthesiaAbdominal NeoplasmsCorticosteroidAntiemeticsFemaleNeurology (clinical)medicine.symptombusinessIntestinal Obstructionmedicine.drug
researchProduct

Systemic moxifloxacin vs amoxicillin/metronidazole adjunct to non-surgical treatment in generalized aggressive periodontitis

2014

Background: The objective of this randomized clinical study was to evaluate the effect of systemic administration of moxifloxacin compared to amoxicillin and metronidazole, combined with non-surgical treatment in patients with generalized aggressive periodontitis (GAgP) in a 6-month follow-up. Material and Methods: A total of 39 systemically healthy patients with GAgP were evaluated in this randomized clinical trial. Periodontal parameters were recorded at the baseline during the 1 st , 3 rd and 6 th month. Patients received either 400 mg of moxifloxacin per os once daily or 500 mg of metronidazole and 500 mg amoxicillin per os three times daily for 7 days consecutively. Results: No signifi…

AdultMalemedicine.medical_specialtyMoxifloxacinOdontologíaGastroenterologylaw.inventionYoung AdultPharmacotherapyRandomized controlled trialAnti-Infective AgentslawMoxifloxacinInternal medicineMetronidazoleMedicineAggressive periodontitisHumansAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industryResearchAmoxicillinAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryMetronidazoleOtorhinolaryngologyAggressive PeriodontitisUNESCO::CIENCIAS MÉDICASSystemic administrationSurgeryDrug Therapy CombinationFemalebusinessmedicine.drugFluoroquinolonesFollow-Up Studies
researchProduct

Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fl…

2005

The safety and efficacy of early bacterial prophylaxis with piperacillin-tazobactam were prospectively evaluated in 51 autologous peripheral blood stem cell transplantation (PBSCT) recipients. The results were compared with those obtained in 51 control patients receiving oral fluoroquinolones in a retrospective matched-pair control study. Overall, 76% of the study group and 98% of the control group developed at least one febrile episode during neutropenia (P=0.002). Time from neutropenia to the first febrile episode (FFE) was significantly longer in the study group than in the control group (P=0.04). Once a febrile episode appeared, the duration of fever was significantly longer in cases th…

AdultMalemedicine.medical_specialtyNeutropeniaAdolescentFevermedicine.drug_classMatched-Pair AnalysisPremedicationAntibioticsPenicillanic AcidBacteremiaGram-Positive BacteriaTazobactamTransplantation AutologousInternal medicineAmphotericin BGram-Negative Bacteriapolycyclic compoundsmedicineHumansAntibacterial agentAgedPiperacillinTransplantationPeripheral Blood Stem Cell TransplantationHematologybusiness.industryHematologyBacterial InfectionsMiddle AgedSurgeryPiperacillin Tazobactam Drug CombinationPiperacillin/tazobactamChemoprophylaxisFemaleStem cellbusinessPiperacillinmedicine.drugFluoroquinolonesBone marrow transplantation
researchProduct

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation

2006

Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions. Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In mult…

AdultMalemedicine.medical_specialtyOral anticoagulationGuidelineRisk AssessmentElectrocardiographyFibrinolytic AgentsRisk FactorsDrug CombinationAntithromboticmedicineHumansOutpatient clinicRisk factorMultivariate AnalysiStrokeRisk stratificationAgedAntithrombotic therapyFibrinolytic AgentFramingham Risk Scorebusiness.industryRisk FactorAtrial fibrillationMiddle Agedmedicine.diseaseAtrial fibrillationStrokeDrug CombinationsMultivariate AnalysisPractice Guidelines as TopicEmergency medicinePhysical therapyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessCardioversionsRisk assessmentHumanEuropean Heart Journal
researchProduct